41 results
8-K
EX-1.1
zk0oibsl8xu9w7nrndk
14 Feb 24
Other Events
4:11pm
8-K
EX-99.2
6uz98g8
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
jd78lc 25j4b0id4sac
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-2.1
6v9aql
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.1
kjhw0
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
424B3
fyd12hevh
28 Aug 23
Prospectus supplement
9:10am
S-4/A
tsch6fpx8l588x5u9tlq
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
n6jmr69vio9u14pu6a72
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-10.5
4uaj7g
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-10.5
150iataig8mpqp1
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
S-3
EX-1.2
7kavbeofch iyocg
1 Oct 21
Shelf registration
4:42pm
D
khgfona0a91e5mb
11 May 21
$27M in equity / options / securities to be acquired, sold $27M, 47 investors
5:20pm